Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs

This article was originally published in The Tan Sheet

Executive Summary

Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.

You may also be interested in...



Mylan Turns To Meda In Sweden For Open Door Into Consumer Market

The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.

Mylan Turns To Meda In Sweden For Open Door Into Consumer Market

The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.

Meda Keeps Traditional Geritol Formula, Tweaks Brand In Re-launch

Meda Consumer Healthcare conducted extensive consumer research on Geritol after acquiring the vitamin supplement brand from GlaxoSmithKline in 2010. Its renamed Geritol Multivitamin SKU retains the original ingredient formulation and appeals to consumers seeking simplicity in the multivitamin space.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel